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Abstract 1 
Three glycosyltransferases have been identified in mammals that can initiate the biosynthesis of Core 2 2 
type protein O-glycosylation.  Core 2 O-glycans are abundant among glycoproteins but to date few 3 
functions for these structures have been identified.  To investigate the biological roles of Core 2 O-4 
glycans, we have generated and characterized mice deficient in one or more of the three known 5 
glycosyltransferases that generate Core 2 O-glycans (C2GnT1, C2GnT2, C2GnT3).  A role for C2GnT1 6 
in selectin ligand formation has been described.  We now report that C2GnT2 deficiency impaired the 7 
mucosal barrier and increased susceptibility to colitis.  C2GnT2 deficiency further resulted in the loss of 8 
all Core 4 O-glycan biosynthetic activity and reduced immunoglobulin abundance.  In contrast, loss of 9 
C2GnT3 altered behavior linked to reduced Thyroxine levels in circulation.  Remarkably, absence of all 10 
three C2GnTs was permissive of viability and fertility.  Core 2 O-glycan structures were reduced among 11 
tissues from individual C2GnT deficiencies and completely absent from triply-deficient mice.  C2GnT 12 
deficiency also induced alterations in I-branching, Core 1 O-glycan formation and O-mannosylation.  13 
Although the absence of C2GnT and C4GnT activities is tolerable in vivo, Core 2 O-glycosylation exerts 14 
a significant influence on O-glycan biosynthesis and is important in multiple physiological processes.   15 
 16 
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 20 
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 22 
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 3 
Introduction 1 
 Protein O-glycosylation is a posttranslational modification implicated in a wide range of 2 
physiological processes including: cell adhesion and trafficking, T-cell apoptosis, cell signaling, 3 
endocytosis and pathogen-host interaction (1, 6, 27, 30, 54, 61, 71).  Core-type protein O-4 
glycosylation is initiated in the secretory pathway by the covalent addition of a N-5 
acetylgalactosamine (GalNAc) to the hydroxyl group of serine or threonine residues by one of 6 
multiple polypeptide N-acetylgalactosamine transferases (ppGalNAcTs) (57, 58).  The 7 
ppGalNAcTs have differences in substrate specificity, with some ppGalNAcT acting 8 
preferentially on specific peptide sequences and others acting only after a GalNAc linkage has 9 
been formed nearby (20, 44).  Following ppGalNAcT action, other glycosyltransferases act, 10 
sequentially and sometimes competitively, to elaborate the repertoire of O-glycan structures (31, 11 
42, 48, 49).   12 
 The Core 2 β1,6-N-acetylglucosaminyltransferases (C2GnTs) and the Core 2 O-glycans 13 
they generate are conserved and widely expressed among mammalian species.  The C2GnTs 14 
operate after Core 1 β-1,3-galactosyltransferase, which adds a galactose in a β1,3-linkage to the 15 
GalNAc-Ser/Thr generating the initial Core 1 O-glycan disaccharide structure (26).  One of the 16 
three C2GnTs (C2GnT1, C2GnT2 and C2GnT3) subsequently adds an N-acetylglucosamine 17 
(GlcNAc) in a β1,6-linkage to the GalNAc to initiate what is known as the Core 2 O-glycan 18 
branch (Figure 1a) (7, 50, 51, 69).  In a distinct pathway, Core 3 β-1,3-N-19 
acetylglucosaminyltransferase (C3GnT) can add a GlcNAc to the unmodified GalNAc to 20 
generate a Core 3 O-glycan (24).  In this case, C2GnT2 can add a GlcNAc in β1,6-linkage to the 21 
GalNAc of the Core 3 O-glycan disaccharide to initiate formation of a Core 4 O-glycan (Figure 22 
1b) (50, 69).  In addition, both C2GnT2 and the I β-1,6-N- acetylglucosaminyltransferase (IGnT) 23 
 4 
are independently capable of forming branched polylactosamine structures  (I-branches) from 1 
otherwise linear polylactosamine glycan chains (Figure 1c) (69).  2 
  C2GnT1-deficient mice have been shown to have an unexpectedly restricted phenotype 3 
with the major defect being leukocytosis reflecting neutrophilia (14).  This appears to be due to a 4 
selective and severe defect in selectin ligand biosynthesis among myeloid cells, leading to 5 
decreased recruitment of neutrophils that further attenuates inflammation and vascular disease 6 
pathogenesis (14, 64).  C2GnT1-deficient mice also exhibit a partial reduction in L-selectin 7 
ligand biosynthesis on high endothelial venules (HEV), resulting in reduced B-cell homing and 8 
colonization of peripheral lymph nodes (18, 21).  Furthermore, thymic progenitors from C2GnT1 9 
deficient mice have a reduced ability to home to the thymus due to loss of P-selectin ligands on 10 
these cells (46).  However, as of yet, the biological functions of C2GnT2 and C2GnT3 have not 11 
been investigated.  To investigate why multiple glycosyltransferases capable of Core 2 O-glycan 12 
formation have been conserved, we have generated mice singly and multiply deficient in the 13 
three C2GnTs, and characterized the resulting physiology and alterations to the glycome.   14 
 15 
Materials and Methods 16 
Mice 17 
Genomic clones isolated from the 129/SvJ mouse strain were used to construct targeting 18 
vectors for Gcnt3, encoding C2GnT2, and Gcnt4, encoding C2GnT3.  To generate individual 19 
targeting vectors for each gene, the genomic clones and the pflox vector were digested with the 20 
appropriate restriction enzymes as indicated (Figure 2).  Each genomic clone was then ligated 21 
into the pflox vector to generate the targeting vector for each gene.  The targeting vectors were 22 
then individually electroporated into R1 ES cells (39).  Homologous recombination between the 23 
 5 
targeting vector and genomic DNA resulted in F[tk-neo] alleles.  G418 (to select for neo gene 1 
expression) was used to select for cells in which the targeting vectors had integrated.  A Cre-2 
recombinase expressing plasmid was electroporated into these cells.  Ganciclovir was used to 3 
select for colonies in which thymidine kinase (tk) was deleted by Cre-recombinase activity. 4 
 Southern blotting of genomic DNA confirmed the expected allelic structures were present. 5 
 Individual chimeric mice were obtained from C57BL/6NHsd blastocytes injected separately 6 
with ES cells containing the alleles in which the single coding exon of interest was flanked by 7 
loxP sites.  Mice carrying these alleles, Gcnt3F or Gcnt4F, in the germline were crossed with 8 
female ZP3-Cre mice to generate separate mice with systematic deletions, Gcnt3Δ/Δ or Gcnt4Δ/Δ.  9 
Experimental mice were on a mixed background of 129Sv/J and C57BL/6NHsd for this reason 10 
littermate control mice were used when ever possible.   11 
 Crossing of single deficient strains generated mice deficient in multiple C2GnTs.    12 
C2GnT1-deficient mice, which have been previously described (14), were crossed to C2GnT3-13 
deficient mice to generate mice heterozygous for both alleles.  These doubly heterozygous mice 14 
were bred to each other to generate mice doubly deficient for C2GnT1 and C2GnT3 (T1/T3).  15 
T1/T3 mice were then bred to C2GnT2-deficient mice to generate mice heterozygous for all 16 
three genes encoding C2GnTs.  Triply heterozygous mice were bred together to generate 17 
offspring doubly deficient for C2GnT1 and C2GnT2 (T1/T2) and doubly deficient for C2GnT2 18 
and C2GnT3 (T2/T3) as well as mice deficient for all three C2GnTs (T1/T2/T3).  Some 19 
T1/T2/T3 mice were used in additional breedings to generate experimental mice.  Animal studies 20 
were accomplished in accordance with Institution Animal Care and Use Committee, University 21 
of California, San Diego. 22 
 23 
 6 
Quantitative-PCR 1 
 RNA was obtained from wild-type C57BL/6NHsd mice.  Tissues were harvested and 2 
stored at -80˚C.  To isolate the RNA the tissue was placed in TRI-Reagent (Sigma, St. Louis, 3 
MO) and homogenized, after homogenization chloroform (Sigma, St. Louis, MO) was added for 4 
extraction.  RNA was pelleted using isopropanol (Sigma, St. Louis, MO) and cleaned using 70% 5 
ethanol.  RNA was dissolved in H2O and treated with Turbo DNA-free (Ambion, Austin, TX) to 6 
remove DNA.  RNA was run on an agarose-formaldehyde gel to determine quality and stored at 7 
-80˚C.  RNA was quantified using OD260 and diluted to 0.5 µg/µl.  qPCR was done as previously 8 
described with slight modifications (36).  cDNA was generated using 1 µg of RNA and 9 
Superscript III First Strand (Invitrogen, Carlsbad, CA).  cDNA product was diluted 1/10 in H2O, 10 
and 1 µl of diluted cDNA plus 0.5 µm primers was used with Brilliant SYBR Green (Stratagene, 11 
Cedar Creek, TX) for the qPCR reaction.  AGGCTCCTCTTCCCTCAAAG was used for the 12 
Gcnt4 forward primer and ACATCACCGTCCTCCAAGTC as the Gcnt4 reverse primer.  13 
Results were standardized using β-actin.  14 
 15 
Selectin ligand expression 16 
 Selectin ligand expression was analyzed as previously described with slight modification 17 
(14, 59).  Chimeras consisting of the lectin domains of mouse E- or P-selectin and the Fc portion 18 
of human IgG (R&D Systems, Minneapolis, MN) were bound to FITC-conjugated anti-human 19 
IgG antibody (Fc specific) (Sigma, St. Louis, MO) in binding media consisting of DMEM 20 
(Gibco) plus 2% IgG-Free BSA (Jackson ImmunoResearch, West Grove, PA) plus 2 mM CaCl2 21 
or 5 mM EDTA, and places in the dark at 4˚C for 30 minutes.  White blood cells were washed 22 
with binding media and then stained with selectin-Fc chimeras prebound to anti-human Fc-FITC.  23 
 7 
Selectin chimera binding to white blood cells was determined by flow cytometry using 1 
FACSCalibur System (BD Biosciences, San Jose, CA).  2 
To activate T-cells, splenocytes were cultured in RPMI media plus 10% bovine serum in 3 
the presence of plate bound anti-CD3 (BD Biosciences, San Jose, CA) and 20 ng/ml IL-2 (R&D 4 
Systems, Minneapolis, MN) for 48 hours.  At the indicated time points, cells were suspended in 5 
binding media and expression of activation markers or selectin ligands was determined by flow 6 
cytometry.    7 
 8 
Hematology 9 
 Hematological parameters were determined utilizing a Hemavet 850FS (Drew Scientific, 10 
Wayne, PA) as previously described (59).  11 
 12 
In vivo mucosal permeability assay 13 
 Mucosal barrier function was determined as previously described (17).  Dextran-FITC 14 
(Sigma, St. Louis, MO) was administered via oral gavage (600 mg/kg) and blood was collected 15 
into Microtainer serum separator tubes (BD, Franklin Lakes, NJ) by retro-orbital bleeds at 4 16 
hours.  Blood was spun down in a tabletop centrifuge at 16.1 x g for 3 min to separate sera.  The 17 
amount of FITC in each sample was measured in duplicate using Spectra Max Gemini EM 18 
fluorescent plate reader (Molecular Devices) at 490 nm and 530 nm for excitation and emission 19 
wavelengths, respectively.        20 
 21 
 22 
 23 
 8 
DSS-induced colitis 1 
 Mice were administered drinking water containing 5% DSS (M.W. 40,000 to 50,000; 2 
USB Corporation, Cleveland, OH) ad libitum and then returned to normal drinking water without 3 
DSS.  DSS was administered for 5 or 6 days.  Occult or overt blood in the stool, stool 4 
consistency, weight and the activity level of the mice were determined daily through out the 5 
experiment and used to calculate disease activity index (DAI) as previously described (22).  6 
Mice surviving to the end of the experiment were then sacrificed, and colons were fixed in 10% 7 
buffered formalin for histological analyses.  The amount of 5% DSS ingested was monitored 8 
daily and did not differ between groups.  Mice that did not drink enough to surpass a DSS-load 9 
of 30mg/day were excluded from the study.  Colon sections were stained with hematoxylin and 10 
eosin (H&E).  The severity of mucosal injury was graded similarly to that described previously 11 
by (38, 40).  Briefly, H&E stained section were read in a blinded manner to determine length of 12 
colon ulceration and crypt damage score.  The injury scale was graded from 0 to III, as follows: 13 
grade 0: normal; grade I: distortion and/or destruction of the bottom third of glands; grade II: 14 
erosions/destruction of all glands or the bottom two thirds of glands and inflammatory infiltrate 15 
with preserved surface epithelium; and grade III: loss of entire glands and surface epithelium.  16 
Results are reported as total length of complete ulceration (grade III damage) and total crypt 17 
damage score as described (22). 18 
  19 
Mucosal protein assays 20 
 A solution containing proteins from the mucosal layer was produced as described with 21 
slight modification (13).  Feces were collected in a clean, empty cage for one hour.  The feces 22 
 9 
were weighed, diluted 20 fold weight to volume in phosphate buffered saline (PBS), and 1 
vortexed to make a fecal solution.  2 
Relative Muc2 levels were determined by ELISA.  Maxisorp 96-well plates (Nunc, 3 
Rochester, NY) were coated overnight at 4˚C with fecal solution diluted 10-fold further with 4 
PBS.  The plates were washed with PBS, blocked with PBS plus 2% IgG-free bovine serum 5 
albumin (BSA; Jackson ImmunoResearch, West Grove, PA) for 1 hour at 22˚C, and then washed 6 
PBS plus 0.05% Tween 20 (PBST; Fisher Scientific, Pittsburg, PA).  Antibody to Muc2 antigen 7 
H-300 (Santa Cruz Biotechnology, Santa Cruz, CA) diluted to 0.2 µg/ml in PBS plus 2% BSA 8 
was then allowed to bind overnight at 4˚C.  The plates were then washed and coated with the 9 
secondary antibody anti-rabbit conjugated to horseradish peroxidase (HRP; Vector Laboratories, 10 
Burlingame, CA) diluted 1/1000 in PBS plus 2% BSA.  Tetramethylbenzidine (TMB; Sigma, St. 11 
Louis, MO) was used as a substrate, and the plates were analyzed at 650 nm using a Versa max 12 
plate reader (Molecular Devices; Sunnyvale,CA).   13 
 14 
Immunoglobulin analyses 15 
 Flat bottom Maxisorp 96-well plates were coated with 5 ug/mL of anti-mouse isotype 16 
specific antibodies (IgM, IgG1, IgG2a, IgG2b, IgG3 and IgA; BD Biosciences, San Jose, CA) in 17 
PBS overnight at 4˚C.  Plates were blocked with 2% BSA.  Sera samples were diluted 1/2,000 18 
(for IgG1, IgG2a and IgA) or 1/10,000 (for IgG3, IgM and IgG2b) in PBS plus 2% BSA and 19 
incubated for 2 hours at 22˚C.  Fecal solutions were diluted 1/100 in PBS plus 2% BSA.  Plates 20 
were washed with PBST.  Alkaline phosphatase (AP)-conjugated antibodies to mouse IgG1, 21 
IgG2a, IgG2b, and IgG3 (BD Biosciences, San Jose, CA) were diluted 1/500 in PBS plus 2% 22 
BSA.   AP-conjugated antibodies to mouse IgM (1/4000) and IgA (1/1000) were purchased from 23 
 10 
Sigma (St. Louis, MO).  Plates were incubated with these secondary antibodies for 1 hour at 1 
22˚C, washed with PBST and then the AP substrate para-nitrophenyl phosphate (Sigma, St. 2 
Louis, MO) was added.  Signals were determined at 405 nm on a Versa max plate reader.   3 
 4 
Behavioral testing 5 
 Behavioral screening included gross physical assessment, analysis of sensorimotor 6 
reflexes and the following assays: acoustic startle, prepulse inhibition, hot plate, tail flick, 7 
conditioned fear, initiation of movement, rotarod, wire hang, grip strength, cage-top hang test 8 
and pole test.  These tests were accomplished as previously reported (3, 28).  In the tube test for 9 
social dominance mice of different genotypes are put into opposite ends of a 30 cm long tube 10 
(29).  The mouse that stays in the tube and causes the other to back out is considered dominant 11 
and said to have “won” the challenge.  If neither mouse backed out of the tube within 60 sec, the 12 
challenge was deemed a “tie.”  Each mouse was challenged three times against 3 different mice 13 
including littermates of the opposite genotype.   14 
 15 
Determination of thyroid hormone levels 16 
 T4 levels were determined by T4 Enzyme Immunoassays (EIA; Monobind Inc., Lake 17 
Forest, CA).  TSH levels were determined by a two-site chemiluminometric assay at Hillcrest 18 
Medical Center of UC San Diego Medical Center.   19 
 20 
Thyroid powder supplemented diet 21 
 Chow was supplemented with 0.025% porcine thyroid powder (Sigma, St. Louis, MO) as 22 
previously described (34) with minor modifications.  The Purina 5053 base diet supplemented 23 
 11 
with 0.025% porcine thyroid powder was purchased from Purina Test Diet (Richmond, IN).   1 
Thyroid powder supplemented chow was fed to wild-type and C2GnT3-deficient mice for 2 2 
weeks in a conventional vivarium.  Mice were analyzed by the tube test for social dominance 3 
prior to and following diet supplementation.  Additionally, sera were collected at both time 4 
points following the tube test for social dominance.  Sera were stored at -20˚C until used to 5 
determine T4 levels.  6 
 7 
TRH stimulation assay  8 
 Mice were stimulated with TRH as previously described (67) with minor modifications. 9 
Blood was obtained at time zero and then mice were immediately administered by intraperitoneal 10 
injection 5 µg/kg of TRH (Sigma, St. Louis, MO) dissolved in 100 µl of PBS.  Blood was then 11 
collected into serum separator tubes (BD, Franklin Lakes, NJ) at 1 or 2 hours and places in a 12 
tabletop centrifuge at 16.1 x g for 3 min to separate sera.  Sera were stored in fresh microfuge 13 
tubes at -20˚C until analyzed.  14 
 15 
T4 half-life assay 16 
  NHS-LC-biotin (10mg/kg of body weight) (Pierce, Rockland, IL) was injected 17 
intravenously into mice to biotinylate circulating proteins as similarly described (19).  Mice were 18 
then bled at time zero.  Blood was collected at additional time points in serum separator tubes.  19 
Sera were stored at -20˚C until assayed.  Glycine was added to sera to quench any additional 20 
NHS activity.  Biotinylated T4 remaining was determined by ELISA.  A flat bottom Maxisorp 21 
plate was coated overnight at 4˚C with anti-T4 antibody (Santa Cruz Biotechnology, Santa Cruz, 22 
CA) diluted 1/1000 in PSB.  The plates were washed with PBS and then blocked overnight at 23 
 12 
4˚C with PBS plus 2% BSA.  Sera samples were incubated on the blocked plates for 1 hour at 1 
22˚C, and the plates were then washed with PBST.  Streptavidin-HRP (BD Biosciences, San 2 
Jose, CA) diluted 1/5000 in PBS plus 2% BSA was allowed to bind for 45 min at 22˚C.  Plates 3 
were washed again, TMB substrate was added, and plates were read at 650 nm using a Versa 4 
max plate reader. 5 
 6 
Enzyme activity assays 7 
 Tissues from freshly sacrificed mice were immediately frozen using dry ice and stored at 8 
-80˚C until used.  C2GnT and C4GnT activities from tissue lysates were determined as 9 
previously described (69).   10 
 11 
Sample preparation for mass spectrometric analysis 12 
Murine tissues were prepared for glycomic screening according to methodology 13 
described previously (56).  Briefly, murine tissues were homogenized with Tris buffer and 14 
sequentially digested with trypsin (Sigma-Aldrich, Dorset, UK) and PNGase F (Roche, West 15 
Sussex, UK).  N-glycans were separated from peptides/ glycopeptides on Sep-Pak cartridges 16 
(Waters, Hertfordshire, UK) and O-glycans were released from the latter by reductive 17 
elimination using KBH4 in KOH.  To optimize O-glycan extraction from mucinous tissues, 18 
especially stomach, the following modifications have been applied on the previous procedure.  19 
Stomach samples were homogenized with water and then glycolipids were extracted out with 20 
methanol and chloroform.  After trypsin digestion, O-glycans were released from the 21 
glycopeptide/peptide pool without N-glycan removal.  Although trace amounts of N-glycans 22 
 13 
might be released together with O-glycans, this strategy enables an improved recovery of O-1 
glycans. 2 
After purification on Dowex columns (Sigma-Aldrich, UK), the O-glycan samples were 3 
permethylated and then further purified with Sep-Pak cartridges.  O-glycans were eluted in 4 
aqueous acetonitrile fractions and then lyophilized.  Glycans are normally eluted in the 35% and 5 
50% acetonitrile fractions, therefore only these fractions were subjected to mass spectrometric 6 
analysis.  All murine tissues were analyzed in duplicates or triplicates. 7 
 8 
Mass spectrometric data acquisition 9 
Permethylated samples were dissolved in 10 µl of methanol.  Then 1 µl of dissolved 10 
sample was pre-mixed with 1 µl of matrix (20 mg/ml 2,5-dihydroxybenzoic acid (DHB) in 70% 11 
(v/v) aqueous methanol) and spotted onto a target plate.  Matrix-assisted laser 12 
desorption/ionization (MALDI) mass spectrometric and tandem mass spectrometric (MS/MS) 13 
data were acquired on a 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosystems) in the 14 
reflectron mode.  The potential difference between the source acceleration voltage and the 15 
collision cell was set to 1 kV and argon was used as collision gas.  The 4700 Calibration 16 
Standard kit, calmix (Applied Biosystems), was used as the external calibrant for the MS mode 17 
and [Glu1]fibrinopeptide B human (Sigma-Aldrich, UK) was used as an external calibrant for the 18 
MS/MS mode. 19 
Comparison of the relative abundance of O-glycans between C2GnT2-deficient, 20 
C2GnT3-deficient and T1/T2/T3 mice with wild type mice of various tissues was done by 21 
comparing peak heights of molecular ions of similar masses and by comparing the total ion 22 
counts of the different classes of glycans.  23 
 14 
Statistical analyses 1 
 Significance in the tube test for social dominance was determined by the chi-square test.  2 
For all other experiments the student’s t-test was used to determine statistical significance. 3 
 4 
Results 5 
Expression of murine Gcnt3 and Gcnt4 RNA 6 
 Glycosyltransferases that generate Core 2 O-glycans are encoded by separate genes each 7 
with a single coding exon in the murine and human genomes.  C2GnT1 is encoded by Gcnt1, 8 
C2GnT2 by Gcnt3, and C2GnT3 by Gcnt4.  The numbering of the genes and the enzymes differ 9 
because the genes were named based on β1,6-GlcNAc transferase activity and the enzymes 10 
based on Core 2 activity.  Gcnt2 encodes IGnT, which has β-1,6-GlcNAc transferase activity but 11 
is not able to generate Core 2 O-glycans, as it is not able to act upon the Core 1 O-glycan as a 12 
substrate (32).   13 
 Analysis of relative expression of Gcnt3 in adult wild-type C57Bl/6Nhsd mouse tissues  14 
by qPCR revealed that Gcnt3 has high relative expression in the gastrointestinal tract, similar to 15 
the previously determined expression pattern of human GCNT3 (69).  Contrary to the expression 16 
of human GCNT4 (51), relatively low levels of the mouse orthologue Gcnt4 were found in the 17 
thymus.  Our studies revealed highest levels of expression of murine Gcnt4 in the small intestine, 18 
liver, and spleen (Figure 1b).  19 
 20 
Germline deletion of Gcnt3 and Gcnt4 21 
 Gcnt3 and Gcnt4 were targeted separately for deletion from the mouse germline.  Gcnt3 22 
was targeted in embryonic stem (ES) cells using Cre-loxP conditional mutagenesis focused on 23 
 15 
the single coding exon of Gcnt3 (Figure 2a).  ES cells in which loxP sites flanked the single 1 
coding exon of Gcnt3 were utilized to generate chimeric mice (Figure 2b).  Gcnt3F mice were 2 
bred to mice expressing Cre-recombinase, under the control of the Zp3 promoter (52), to 3 
generate mice with a systematic deletion of Gcnt3 (Gcnt3Δ).  C2GnT2-deficient mice (Gcnt3Δ/Δ) 4 
were viable, born at normal Mendelian ratios, and both genders were fertile.   5 
 The single coding exon of Gcnt4 was similarly targeted using the Cre-loxP mutagenesis 6 
approach (Figure 2c).  Chimeric mice were generated with ES cells that carried the Gcnt4F allele 7 
(Figure 2d).  Breeding to Zp3-Cre mice was again utilized to produce offspring carrying the 8 
Gcnt4Δ allele in the germline (Figure 2d).  Both genders of mice homozygous for the Gcnt4Δ 9 
allele were also born at expected Mendelian ratios without overt developmental abnormalities 10 
and exhibited normal fecundity as adults.   11 
 12 
Hematology and selectin ligand biosynthesis in mice lacking either C2GnT2 or C2GnT3 13 
 As the selectin ligand biosynthesis defect in C2GnT1 deficient mice is incomplete, and as 14 
there is precedence for collaboration among glycosyltransferases in the biosynthesis of selectin 15 
ligands (35, 45), we analyzed mice lacking either C2GnT2 or C2GnT3 for signs of a selectin 16 
ligand defect.  Hematological analyses revealed that C2GnT3-deficient mice (Gcnt4Δ/Δ), but not 17 
C2GnT2-deficient mice, exhibited slight, but significant neutrophilia.  No other alterations in 18 
hematological profiles were evident in mice singly deficient for C2GnT2 or C2GnT3 (Figure 3a).  19 
Additionally, no overt differences were observed in the cellularity of various immune tissues 20 
including in the peripheral lymph nodes, or in the expression of various markers on immune cells 21 
including B220 (data not shown).  To determine if the neutrophilia exhibited by C2GnT3-22 
deficient mice is a result of reduced selectin ligand biosynthesis in the absence of C2GnT3, 23 
 16 
selectin ligand expression on neutrophils from C2GnT3-deficient mice was analyzed.  Using 1 
flow cytometric measurements, neutrophils from these mice expressed unaltered P- and E-2 
selectin ligands (Figure 3b).  C2GnT2-deficient neutrophils also normally expressed ligands for 3 
P- and E-selectins (Figure 3c).  In addition, the homeostasis of thymocytes within C2GnT3-4 
deficient mice was unaltered (Figure 3d).   C2GnT3-deficient thymocytes also exhibited normal 5 
expression of cell surface markers including 1B11, which is partly dependent upon Core 2 O-6 
glycosylation (8) (Figure 3e).  As selectin ligand expression is upregulated by activated T-cells 7 
and C2GnT3 is expressed in activated T-cells (36), we analyzed the expression of selectin 8 
ligands on activated C2GnT3-deficient T-cells.  Upon stimulation with plate bound anti-CD3 9 
antibody in the presence of IL-2, C2GnT3-deficient T-cells upregulated activation markers 10 
including CD69 and 1B11 similarly to activated wild-type T-cells (Figure 3f).  Selectin ligand 11 
expression, as determined by cytometry, was also unaltered among these activated T-cells, 12 
revealing that C2GnT3 is not required for upregulation of selectin ligands under these conditions.  13 
 14 
C2GnT2 deficiency impairs mucosal barrier function and increases pathogenesis of 15 
experimental colitis 16 
 As Gcnt3 is relatively highly expressed in tissues with high epithelial cell content, we 17 
suspected that the gastrointestinal tract might be affected in C2GnT2 deficiency.  In fact, 18 
C2GnT2-deficient mice, but not C2GnT3-deficient mice, were found to have increased mucosal 19 
permeability indicating a defect in the mucosal barrier (Figure 4a and data not shown).  To test 20 
the ability of the gastrointestinal tract of C2GnT2-deficient mice to protect from chemically 21 
induced colitis, we used dextran sodium sulfate (DSS) to experimentally induce disease (22).  22 
There was a trend towards increased weight loss in C2GnT2-deficient mice treated with DSS 23 
 17 
(Figure 4b).  Also, on at least one day during each separate experiment the disease activity score 1 
for C2GnT2-deficient mice was significantly worse than for similarly treated wild-type 2 
counterparts (Figure 4c).  At the end of the experiment, H&E stained colon sections were used to 3 
determine length and grade of ulceration in these tissues.  DSS-treated C2GnT2-deficient mice 4 
exhibited significantly more colon damage with increased ulceration and increased damage to the 5 
crypts in the colon (Figure 4d, 4e and 4f). 6 
 Mucins, glycoproteins that derive a majority of their molecular weight from O-glycans, 7 
have been implicated in mucosal barrier function and protection from DSS-induced colitis (47, 8 
60).  However, the expression of Muc2, the major secretory mucin in the colon, is not reduced 9 
among mice deficient in C2GnT2 (Figure 4g).   10 
 11 
Immunoglobulin deficiencies in the absence of C2GnT2 12 
 Levels of IgG1, IgG2a, and IgG2b were significantly reduced in the serum of C2GnT2-13 
deficient mice (Figure 5a).  There is also a trend towards decreased serum levels of IgG3 and 14 
IgA.  In contrast to circulating IgA, mucosal IgA abundance was significantly decreased in 15 
C2GnT2-deficient mice (Figure 5b).  Altered mucosal immune homeostasis, including the 16 
absence of mucosal immunoglobulins, has previously been associated with susceptibility to DSS-17 
induced colitis (9, 37).  Absence of C2GnT2 results in a defect in the immune system, 18 
characterized by a reduction in immunoglobulin levels that may be associated with an increase in 19 
disease susceptibility.    20 
 21 
 22 
 23 
 18 
C2GnT3-deficient mice exhibit a behavioral abnormality linked to reduced Thyroxine levels 1 
 Increased fighting was observed between male mice in litters containing at least one 2 
C2GnT3-deficient animal, but not among litters that included C2GnT2-deficient mice.  The 3 
behavior of male mice lacking C2GnT3 was further analyzed.  C2GnT3-deficient male mice 4 
exhibited a significant increase in social dominance compared to wild-type male littermates 5 
(Figure 6a).  This assay is often used as a measure of aggression (10).  Hypothyroidism is one 6 
cause of aggression in mammals including dogs and horses (4, 12, 15, 62).  Further phenotype 7 
screening revealed that C2GnT3-deficient mice had a slight but significant decrease of 8 
circulating Thyroxine (T4) levels (Figure 6b).  To determine if the altered behavior observed in 9 
C2GnT3 deficiency was a result of insufficient T4 abundance, we fed C2GnT3-deficient mice 10 
and wild-type littermates chow supplemented with 0.025% porcine thyroid powder (34).  Wild-11 
type and C2GnT3-deficient mice fed thyroid-powder supplemented chow achieved similar 12 
circulating T4 levels (Figure 6c).  When these mice were retested in the social dominance assay, 13 
no difference between C2GnT3-deficient and wild-type mice was observed (Figure 6d).  This 14 
finding indicates that the altered behavior observed in C2GnT3-deficient mice is likely due to 15 
reduced T4 levels in circulation.   16 
 The thyroid is stimulated to release T4 in response to secretion of Thyroid Stimulating 17 
Hormone (TSH) from the pituitary.  Thus we investigated the abundance of TSH in circulation in 18 
C2GnT3-deficient mice.  No difference was observed in circulating TSH abundance (Figure 6e).  19 
Reduced levels of circulating T4, in the presence of normal levels of TSH, suggests secondary 20 
hypothyroidism because thyroid hormone regulation involves a negative feedback loop in which 21 
T4 feeds back to the pituitary to reduce TSH secretion (11, 16).  Secondary hypothyroidism can 22 
be tested by stimulation with thyrotropin-releasing hormone (TRH), the hormone secreted from 23 
 19 
the hypothalamus that stimulates the pituitary to release TSH (41, 67).  No differences were 1 
present in the levels of T4 secreted in response to TRH stimulation among wild-type and 2 
C2GnT3-deficient mice (Figure 6f).  This suggests that the slight reduction in T4 levels may not 3 
be sufficient to increase TSH levels via the negative feedback loop.   4 
 The mild hypothyroidism in C2GnT3-deficient mice may not be a result of secondary 5 
hypothyroidism despite normal levels of TSH.  To determine if T4 levels are reduced due to 6 
decreased half-life in circulation, we compared the in vivo half-life of T4 in wild-type and 7 
C2GnT3-deficient mice.  No difference in T4 half-life in wild-type and C2GnT3-deficient mice 8 
was detected (Figure 6g).  9 
 10 
Mice deficient for all three C2GnTs are viable 11 
 The extent to which the three known glycosyltransferases with C2GnT activity can 12 
biologically compensate for each other is unknown, thus we chose to generate mice deficient for 13 
multiple C2GnTs.  As these three Gcnt genes reside on different chromosomes, we accomplished 14 
this by crossing the single deficient states to each other.  All three possible C2GnT doubly 15 
deficient combinations (T1/T2, T1/T3, T2/T3) were generated, and these animals were born 16 
without overt abnormalities and appeared normal.  From these parental sources, offspring should 17 
theoretically include triple-null littermates (T1/T2/T3).  Remarkably, mice deficient in all three 18 
C2GnTs were born viable and appeared to develop normally to adults.  In addition, both male 19 
and female T1/T2/T3 mice were fertile (data not shown). 20 
 21 
 22 
 23 
 20 
C2GnT and C4GnT activity in C2GnT deficient mice 1 
 C2GnT2 and C2GnT4 enzymatic activity levels were determined among tissue lysates 2 
from animals bearing single and multiple C2GnT deficiencies.  C2GnT2-deficient colon and 3 
mesenteric lymph node samples contained significantly reduced C2GnT activity compared to the 4 
level of activity in wild-type lysates (Figure 7a).  Furthermore, no significant C4GnT activity 5 
was detected in any tissue tested from C2GnT2-deficient mice, implying that C4GnT activity is 6 
produced exclusively by C2GnT2 (50, 69).  In contrast, no significant decrease in C2GnT 7 
activity was measured among various tissues analyzed from C2GnT3-deficient mice, despite the 8 
fact that the entire coding region of C2GnT3 was similarly deleted (Figure 7b).  Nevertheless, 9 
very little C2GnT activity was detected in tissues from mice deficient for all three C2GnTs 10 
(Figure 7c).   11 
 12 
O-glycans structures in C2GnT deficiency 13 
 O-glycan structures from C2GnT2 and C2GnT3 singly deficient mouse tissues were 14 
compared to wild-type samples using mass spectrometric glycomic methodologies (25).  The O-15 
glycan structural changes reported herein have been selected among a larger number of 16 
alterations with a focus on the major defects observed.  The full O-glycomes of each tissue 17 
remain to be established but will be reported elsewhere.  Decreases in Core 2 O-glycan 18 
structures, along with increases in various Core 1 O-glycan structures, were clearly detected in 19 
C2GnT2-deficient stomach, colon, and small intestine samples (Table I).  In C2GnT2-deficient 20 
stomach and colon tissues, the increased abundance of Core 1 structures included elongated Core 21 
1 branches, several of which bore polylactosamine.  In contrast, in the small intestine non-22 
elongated, sialylated Core 1 O-glycan structures were increased.  Furthermore, stomach and 23 
 21 
colon tissues from C2GnT2-deficient mice exhibited a decrease in I-branching.  Surprisingly, 1 
elongated O-mannose structures were detected in the stomach of C2GnT2-deficient mice but not 2 
wild-type counterparts.  O-glycans structures from C2GnT2-deficient kidney samples were 3 
unaltered as compared to wild-type kidney structures, consistent with the relative expression of 4 
murine C2GnT2. 5 
 C2GnT3-deficient tissues contained O-glycan structural changes in the small intestine, 6 
stomach and thyroid/trachea samples with decreases in the relative abundance of some Core 2 O-7 
glycan structures relative to Core 1 O-glycan structures in these tissues.  No substantial changes 8 
in O-glycan structures were noted in the thymus, colon, kidney or liver from C2GnT3-deficient 9 
mice (Table I and data not shown).  These findings revealed that even in tissues with high 10 
relative expression of C2GnT3, loss of this glycosyltransferase did not lead to marked changes in 11 
O-glycan structures.  12 
 Tissues from T1/T2/T3 mice deficient in all three known C2GnTs lacked all detectable 13 
Core 2 O-glycan structures among all tissues surveyed including the colon, small intestine, 14 
stomach, and kidney (Table I).  These results indicate that no other glycosyltransferases appear 15 
capable of synthesizing Core 2 O-glycans in vivo.  Furthermore, small intestine, stomach, and 16 
colon samples from T1/T2/T3 mice had a further increase in elongated Core 1 O-glycans 17 
compared to tissues lacking a single C2GnT.  Surprisingly, no O-glycan structures containing I-18 
branches were detected in stomach and colon samples from T1/T2/T3 mice.  There was also an 19 
unexpected increase in elongated O-mannose structures in the stomach of T1/T2/T3 mice, even 20 
in comparison with C2GnT2-deficient stomach samples.   21 
  22 
23 
 22 
Discussion 1 
 The presence of three conserved genes encoding glycosyltransferases that can initiate the 2 
biosynthesis of Core 2 O-glycans suggests that each C2GnT may provide significant 3 
compensation for each other as afforded by this close overlap in enzymatic activity.  However, 4 
the different expression profiles of each C2GnT among tissues and cell types, as well as some 5 
inherent enzymatic differences, also suggests unique biological roles may exist involving each 6 
C2GnT glycosyltransferase.  By generating mice singly and multiply deficient in C2GnT 7 
activities, we have developed models to study the structure and function of O-glycosylation as 8 
controlled by C2GnT activity.  Core 2 and perhaps Core 4 O-glycans produced by C2GnT2 9 
operate in establishing the epithelial mucosal barrier and reduce disease signs following chemical 10 
induction of colitis.  Alterations in humoral and mucosal immune system homeostasis were 11 
present and may be related to these findings.  In contrast, C2GnT3 does not provide a role in 12 
formation or maintenance of the mucosal barrier, but instead its deficiency alters behavorial 13 
phenotypes linked with reduced T4 Thyroxine abundance in circulation.  Neither C2GnT2 nor 14 
C2GnT3 appear to function in the biosynthesis of selectin ligands, unlike previous findings in 15 
mice lacking C2GnT1 (14). Each C2GnT glycosyltransferase has different biological roles as 16 
evidenced in these physiological systems in vivo.  Both expected and unexpected changes 17 
occurred in the repertoire of O-glycans detected among multiple tissues from animals deficient in 18 
C2GnT activity.  These structural alterations of the glycome will aid in identifying further the 19 
mechanistic features of O-glycan biosynthesis and the etiology of these phenotypes.   20 
 21 
22 
 23 
Distinct and potential overlapping functions of C2GnTs 1 
 Neutrophila in the absence of a measured defect in selectin ligand expression by 2 
cytometry in C2GnT3-deficient mice is reminiscent of mice deficient for 3 
α(1,3)fucosyltransferase-IV (FucT-IV).  In contrast, no hematological or selectin ligand 4 
biosynthetic defect was observed in C2GnT2 deficiency.  Mice deficient for FucT-IV also 5 
exhibited a slight increase (20%) in neutrophils in circulation without measurable decreases in 6 
binding of selectin chimeras to neutrophils (23).  Nevertheless, FucT-IV was shown to contribute 7 
to selectin ligand function in vivo, as FucT-IV-deficiency increased selectin-dependent leukocyte 8 
rolling velocity in microvessels (65).  It remains possible that C2GnT3 contributes to selectin 9 
ligand formation detectable by additional studies and approaches.  Alternatively, C2GnT3 may 10 
modulate neutrophil abundance in circulation by altering myelopoiesis.  Several cell adhesion 11 
molecules, including selectins and sialomucins, have been found influence hematopoiesis and 12 
altered glycosylation has been shown to increase neutrophil production (23, 53, 63).  This may 13 
reflect altered binding between lectins and glycoproteins in the context of stem cell turnover and 14 
differentiation.  Nevertheless, the degree of increase observed among circulating neutrophils per 15 
se in C2GnT3-deficient mice is unlikely to significantly alter physiology.  16 
Decreased mucosal barrier function is associated with Inflammatory Bowel Diseases 17 
(IBDs) (33, 55), including colitis.  It is possible that the increased mucosal permeability and 18 
disease signs that occur with DSS treatment are related in C2GnT2-deficient mice.  Moreover, 19 
the single C3GnT glycosyltransferase that generates Core 3 O-glycans is also essential for 20 
mucosal barrier function and similarly decreases susceptibility to DSS-induced colitis (2).  In 21 
C3GnT-deficient mice, those findings were attributed to reduced abundance of Muc2, a mucin 22 
known to be necessary for protection from colitis (2, 60).  In contrast, C2GnT2 deficient mice 23 
 24 
did not appear to have decreased expression of Muc2.  Susceptibility to IBDs is associated with 1 
factors other than altered mucin levels, including changes in commensal and pathogenic 2 
organisms as well as altered immune system homeostasis (43, 66).  In C2GnT2-deficient mice, 3 
the impaired humoral immune homeostasis exhibited by reduced serum IgG1, IgG2a, IgG2b, and 4 
mucosal IgA levels may indicate or contribute somehow to increased susceptibility to 5 
experimental colitis.  Furthermore, as high relative expression of C2GnT2 is prominent among 6 
tissues with high epithelial cell content, it is possible that the decrease in some immunoglobulin 7 
subtypes is due to a defect of the mucosal immune system.  Perhaps the C2GnT2 and C3GnT 8 
glycosyltransferases collaborate to enforce the mucosal epithelial barrier.   9 
 Several mechanisms may explain the reduced T4 Thyroxine abundance in C2GnT3-10 
deficient mice.  Alterations in the T4 negative feedback loop could lead to decreased T4 11 
abundance in the presence of normal TSH levels.  Alternatively, it remains possible that 12 
decreased T4 half-life or T4 secretion in response to TSH stimulation in C2GnT3 deficiency 13 
occurs at levels below experimental detection.  Additional studies that include analyses of T4-14 
carrier proteins may further resolve this.  From our findings it remains possible that overly 15 
aggressive behavior linked to decreased T4 abundance may be among the first symptoms to 16 
develop in some cases of hypothyroidism.  17 
While mice singly deficient for C2GnT1, C2GnT2 or C2GnT3 exhibited distinct 18 
phenotypes, the presence of novel phenotypes in mice deficient for multiple C2GnTs, but not 19 
present in any of the singly deficient models, would reveal collaboration and compensation 20 
among these glycosyltransferases in physiologic processes.  Preliminary data indicates that 21 
T1/T2/T3 mice are unqiue among the other lesser deficiency states with elevated levels of the 22 
liver enzyme alanine transaminase (ALT), implying changes in liver function apparent only in 23 
 25 
the absence of all three C2GnTs (unpublished observation).  Defining the biological mechanisms 1 
of the phenotypes evoked by the loss of C2GnT activity will require additional resolution that is 2 
afforded by linking glycan structures to normal and pathologic contexts.   3 
 4 
Structural basis of O-glycan biosynthesis determined by C2GnT1, C2GnT2 and C2GnT3 5 
  The absence of any single C2GnT glycosyltransferase results in a reduction of Core 2 O-6 
glycan structures in one or more tissues in vivo.  By comparison, the decrease in Core 2 O-glycan 7 
structures in C2GnT3-deficient tissue samples was modest and C2GnT activity was not 8 
mearsurable decreased in these tissues.  This suggests that C2GnT3 may have a relatively minor 9 
contribution to Core 2 O-glycan biosynthesis in these tissue types in vivo.  Core 2 O-glycan 10 
structures were totally absent from tissues lacking all three C2GnTs.  Interestingly, tissue lysates 11 
from these triply-deficient animals harbored a small amount of C2GnT enzymatic activity.  This 12 
suggests the possibility that another unidentified glycosyltransferase may have a low level of 13 
C2GnT activity when assayed in vitro.  Nevertheless, the absence of Core 2 O-glycan structures 14 
in T1/T2/T3 mice indicates that no additional glycosyltransferases exist that can generate Core 2 15 
O-glycans in vivo as detected by our analyses. 16 
  C2GnT deficiency further altered the repertoire and abundance of O-glycan structures 17 
not directly generated by C2GnTs and produced by different biosynthetic pathways.  The large 18 
decrease in the abundance of I-branching on O-glycan structures from stomach and colon tissues 19 
of mice lacking C2GnT2 suggests that in some tissues C2GnT2, and not IGnT, is the dominant I-20 
branching glycosyltransferase in protein O-glycosylation.  The further degree of loss of I-21 
branching in stomach and colon samples from mice lacking all three C2GnTs implies that either 22 
C2GnT1 or C2GnT3 may also have I-branching activity in vivo.  In this regard, C2GnT3 has 23 
 26 
been characterized with a low level of I-branching activity in vitro (51).  The repertoire of Core 1 1 
O-glycans and O-mannosylated glycans were also altered among various tissues.  The increase of 2 
Core 1 O-glycan structures and their elongation in the absence of one or more C2GnTs was 3 
linked with the formation of polylactosamines that may alter lectin-dependent binding and 4 
physiology.  This elaboration of Core 1 O-glycans is not likely due to reduced competition for 5 
acceptor substrates in the Golgi apparatus, as the formation of the Core 2 O-glycan branch does 6 
not decrease the efficiency of Core 1 extension enzyme-β1,3-N-acetylglucosaminyltransferase 7 
(C1GnT) (68).  Alternate explanations include possible the possible elevation of C1GnT activity 8 
or perhaps an increase in the availability of the common UDP-GlcNAc donor substrate, which is 9 
also used in the process protein O-mannosylation (70, 72).  Core 4 O-glycan structures if present 10 
exist below the level of detection in wild-type and C2GnT deficient tissues, thus it is not 11 
currently known whether the loss of C4GnT activity in C2GnT2 deficiency correlates with a 12 
reduction or absence of Core 4 O-glycans in vivo. 13 
 Core 2 O-glycans have been associated with interactions among commensal and 14 
pathogenic bacteria, and their hosts.  Loss of C2GnT2 may alter the ability of commensal or 15 
pathogenic bacteria to colonize the host.  Recently it has been shown that Helicobacter pylori 16 
and Clostridium perfringens express proteins that bind to Core 2 O-glycans (5, 27).  Preliminary 17 
data also suggests that C2GnT3 may be required for T-cell responses to an intestinal challenge 18 
(H. Ziltener, personal communication).  These findings may relate to the phenotypes we have 19 
thus far reported in C2GnT deficiency states and suggest that challenging these animals with 20 
additional stimuli may further reveal novel biological roles of Core 2 O-glycans.  Nevertheless, 21 
the relatively mild impact of Core 2 O-glycan deficiency in vivo may reflect partial to full 22 
compensation provided by the resulting induction of extended Core 1 and o-mannosylated O-23 
 27 
glycan structures, as was similarly established in the formation of selectin ligands on estended 1 
Core 1 O-glycans in C2GnT-1 deficiency (68).  C2GnT deficiency modeled among intact mice 2 
has contributed substantially to understanding the biosynthesis and functions of protein O-3 
glycosylation in vivo.  Each of the three glycosyltransferases with C2GnT activity has a distinct 4 
function, and thus begins to explain why three separate genes encoding C2GnT enzymes have 5 
been selected and conserved in mammalian evolution.  6 
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Figure 1 1 
Activity and expression of C2GnTs 2 
(a-c) Monosaccharides are depicted as geometric shapes with GalNAc as a yellow square, 3 
galactose as a yellow circle, and GlcNAc as a blue square.  In addition, the vertical arrows 4 
indicate that each branch can be further elaborated by additional saccharide linkages.   5 
(a) Biantennary Core 2 O-glycans are generated when any of the three C2GnTs acts on the Core 6 
1 O-glycan disaccharide.  (b) C2GnT2 can generate Core 4 O-glycans from Core 3 O-glycans by 7 
adding a GlcNAc to the initiating GalNAc.  (c) C2GnT2, in addition to IGnT, also has the ability 8 
to generate branched polylactosamine repeats from linear polylactosamine repeats.  The figure 9 
depicts distal I-branching as the GlcNAc is transferred to the predistal galactose, the preferential 10 
I-branching activity of C2GnT2.  However, IGnT preferentially has central I-branching activity 11 
that adds GlcNAc on the internal galactose in Galβ1➝4GlcNAcβ1➝3Gal-R (69).  (d) RNA 12 
expression of murine Gcnt3 (left panel) and Gcnt4 (right panel), which code for C2GnT2 and 13 
C2GnT3, respectively, as determine by qPCR.  Data is graphed relative to testes expression.  All 14 
values are means ± S.E.M. 15 
 16 
Figure 2 17 
Generation of mice singly deficient for C2GnT2 or C2GnT3 18 
(a) Gcnt3 genomic clone from 129/SvJ mouse strain was used to generate a targeting construct 19 
using the pflox vector as indicated.  B: Bgl II, Ba: Bam HI, E: Eco RI, S: Spe I, X: Xba I, Xh: 20 
Xho I.  (b) Southern blotting of genomic DNA confirms the Gcnt3 allele structure present in ES 21 
cells using the genomic probe (top).  Southern blotting with a loxP probe detects the location and 22 
number of loxP sites (bottom).  (c) The targeting of the single coding exon of Gcnt4 using the 23 
 43 
pflox vector in depicted.  A: Age I, B: Bam HI, E: Eco RV, S: Sac I, Sa: Sal I, St: Stu I, X: Xho 1 
I.  (d) Southern blots of genomic DNA with the genomic probe (top) or loxP probe (bottom) 2 
indicate the structure of Gcnt4 alleles present. 3 
 4 
Figure 3 5 
Selectin ligand expression on neutrophils and T-cells from C2GnT-deficient mice 6 
(a) Hematological levels in mice single deficient for C2GnT2 or C2GnT3 relative to wild-type 7 
levels are graphed.  (b and c) Histograms depict the expression of ligands for P- and E-selectins 8 
on neutrophils from mice singly deficient for (b) C2GnT3 or (c) C2GnT2.  Addition of EDTA 9 
controls for binding of C-type lectins.  (d) Number of thymocytes of each cell type in wild-type 10 
and C2GnT3-deficient mice is graphed (DN: CD4-, CD8- cells; DP: CD4+, CD8+ cells; SP: CD4+ 11 
or CD8+ cells).  (e) Expression of the 1B11 antigen on thymocyte sub-populations is shown.  (f) 12 
Histograms indicate the level of expression of activation markers and selectin ligands on 13 
activated wild-type and C2GnT3-deficient T-cells.  All values are means ± S.E.M. (*p<0.05) 14 
 15 
Figure 4 16 
Barrier function and colitis in C2GnT2-deficient mice 17 
(a) The amount of dextran-FITC in sera four hours after administration by gavage is graphed. 18 
Data shown is from a minimum of 6 mice per a genotype.  (b) Graph shows the average percent 19 
weight change as compared to t=0 of wild-type (closed squares) and C2GnT2-deficient (open 20 
squares) mice during and following treatment with 5% DSS until onset of mortality.  The 21 
horizontal line represents the time of the DSS treatment.  DSS was given to 6 mice of each 22 
genotype.  (c) DAI of wild-type and C2GnT2-deficient mice treated with 5% DSS is graphed.  23 
 44 
(d) The length of grade III damage (total ulceration with loss of glands and surface epithelium) in 1 
colon sections from of DSS-treated wild-type and C2GnT2-deficient mice is shown.  (e) The 2 
average crypt damage score is graphed.  (f) Representative H&E stained colon sections from 3 
DSS-treated wild-type mice (illustrating grade II and grade I crypt damage) and C2GnT2-4 
deficient mice (illustrating grade III crypt damage or total ulceration).  (g) Relative mucosal 5 
Muc2 levels from untreated wild-type and C2GnT2-deficient mice is graphed.  All values are 6 
means ± S.E.M.  S.E.M. is represented by capped and uncapped vertical lines.  (p<0.05) 7 
 8 
Figure 5 9 
Circulating and mucosal immunoglobulins in wild-type and C2GnT2-deficient mice.  10 
(a) Circulating levels of immunoglobulins of the IgM, IgG1, IgG2a, IgG2b, IgG3 and IgA isotypes 11 
in wild-type and C2GnT2-deficient mice is graphed.  Data shown is pooled from two separate 12 
experiments, each of at least 5 mice of each genotype per an experiment.  (b) Mean mucosal IgA 13 
levels in wild-type and C2GnT2-deficient mice fecal samples is graphed.  All values are means ± 14 
S.E.M. (*p<0.05)  15 
 16 
Figure 6 17 
Behavior and thyroid function in C2GnT3-deficient mice 18 
(a) Results from the tube test for social dominance are graphed.  The results shown are 19 
representative of three separate experiments.  (b) Mean circulating T4 levels in wild-type and 20 
C2GnT3-deficient mice is graphed.  (c) Mean circulating T4 levels in wild-type and C2GnT3-21 
deficient mice following diet supplementation with 0.025% thyroid powder for 2 weeks is 22 
shown.  (d) Outcome of social dominance assay performed with wild-type and C2GnT3-deficient 23 
 45 
mice treated with 0.025% thyroid powder supplemented chow is shown.  (e) Mean circulating 1 
levels of the TSH in wild-type and C2GnT3-deficient mice is graphed.  (f) Average amount by 2 
which TRH stimulation increased T4 in circulation after 1 and 2 hours in wild-type and 3 
C2GnT3-deficient mice is shown.  (g) The mean relative amount of biotinylated T4 remaining at 4 
each time point is graphed.  All capped and uncapped error bars represent S.E.M.  (*p<0.05; 5 
**p<0.01)  6 
 7 
Figure 7 8 
Enzyme activity in tissue lysates from mice deficient for C2GnTs 9 
(a) Relative C2GnT and C4GnT activity in tissue lysates from C2GnT2-deficient mice is 10 
graphed.  (b and c) C2GnT activity in tissue lysates from (b) C2GnT3-deficient and (c) triply 11 
deficient mice relative to activity in wild-type control tissues is shown.  Values represent means 12 
± S.E.M. (*p<0.05, ***p<0.001) 13 
 14 
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Structural characteristics Examples of structure
Changes relative to WT
C2GnT2∆/∆ C2GnT3∆/∆ T1/T2/T3
Stomach
Core 2 -ser/thr -ser/thr  = ND
Elongated Core 1 -ser/thr
-ser/thr
=
I- Branches
-ser/thr
-ser/thr
= ND
Elongated O-mannose -ser/thr -ser/thr =
Colon
Core 2 -ser/thr -ser/thr = ND
Elongated Core 1 -ser/thr
-ser/thr
=
I- Branches
-ser/thr -ser/thr = ND
Small Intestine
Core 2 -ser/thr
-ser/thr
ND
Core 1 & Elongated Core 1 -ser/thr
-ser/thr
Kidneys
Core 2 -ser/thr -ser/thr = = ND
Core 1 & Elongated Core 1 -ser/thr -ser/thr = = =
Thyroid / Trachea
Core 2 -ser/thr -ser/thr NA NA
Core 1 & Elongated Core 1 -ser/thr -ser/thr NA NA
Sda -ser/thr -ser/thr NA NA
Thymus
Core 2 -ser/thr -ser/thr NA = NA
Core 1 & Elongated Core 1 -ser/thr -ser/thr NA = NA
Table I. O-glycan structures in the presence and absence of C2GnTs
The structural changes described here are based on MALDI-TOF/TOF MS and MS/MS data. WT, wild-type 
mice; C2GnT2∆/∆, C2GnT2-deficient mice; C2GnT3∆/∆, C2GnT3-deficient mice; T1/T2/T3, C2GnT triple-deficient 
mice; NA, not analysed; ND, none detected; =, no significant changes; ser, serine; thr, threonine; upward arrows 
represent increase; downward arrows represent decrease; the number of arrows is indicative of the magnitude 
of change with 3 arrows being the greatest (>75%) and 1 arrow the smallest (<25%) percent of change from wild 
type. Linkages are assigned according to the biosynthetic pathways known. , N-acetylgalactosamine (GalNAc); 
, N-acetylglucosamine (GlcNAc); , GalNAc or GlcNAc; , galactose; , mannose; , N-acetylneuraminic 
acid; , N-glycolylneuraminic acid; , fucose.
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